The Latest Breaking News from MCK

Despite Cardinal Health’s underperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

McKesson has underperformed the S&P 500 over the past year, but analysts are highly optimistic about the stock’s prospects.

McKesson (MCK) reported consistent revenue growth and solid profit margins in the last reported quarter, supported by robust demand for pharmaceuticals and medical supplies and efficient cost management. With nearly 25% year-to-date gains, should you invest in this healthcare stock? Read on to learn more….

There are good reasons to invest in the long-term potential of these growth stocks.

While changes to the iGaming market in Ontario were being heralded as a success by the province and commercial gambling operators alike, there has been a battle going on in the background.

Author's Note: Sometimes a stock will come up continually on my screeners. MCK was featured 10/16/2023 when it was trading at $462.56. The stock has gained 30%+ since then. The Chart of the Day belongs to the healthcare medical distribution company McKesson (MCK) . I found the stock by using...

McKesson has outperformed other healthcare stocks over the past three months, and analysts remain optimistic about the stock’s prospects.

June S&P 500 E-Mini futures (ESM24) are up +0.09%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.02% this morning after three major U.S. benchmark indices ended the regular session higher as recent U.S. jobs data and remarks from Federal Reserve officials buoyed rate-cut hopes while investors awaited further…

Given the growing demand for healthcare facilities, rapid integration of digital technology, and transformative biotechnology breakthroughs, the medical industry is poised for continued growth and profitability this year and beyond. Amid this, let’s find out why investors are flocking to medical stocks Vertex Pharmaceuticals (VRTX) and McKesson (MCK). Read more….